Maintenance of increased coronary blood flow in excess of demand by nisoldipine administered as an intravenous infusion by Soward, A.L. et al.
Maintenance of Increased Coronary Blood 
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and PATRICK W. SERRUYS, MD 
Systemic and hemodynamic effects of nisoldipine, 
administered as a 4.5pg/kg intravenous bolus over 
3 minutes followed immediately by an infusion of 
0.2 pg/kg/min over 30 minutes, were studied in 13 
patients undergoing diagnostic catheterization for 
suspected coronary artery disease or follow-up 
catheterization after coronary angioplasty. Re- 
sponses to the drug tended to be exaggerated in the 
first 8 minutes of the infusion, but thereafter pro- 
duced a steady state, with heart rate increased by 
14 f 3% at 18 minutes and by 15 f 3% at 24 
minutes (p <0.05), mean aortic pressure de- 
creased 12 f 2 % and 13 f 3% at the same 
times (p <0.05) and coronary venous blood flow 
increased by 31 f 5% and 34 f 8% (p <0.05). 
Myocardial oxygen consumption and the heart rate- 
systolic aortic pressure product were unchanged 
and cardiac output and stroke volume were signifi- 
cantly increased. Study during matched coronary si- 
nus pacing produced similar trends. Nisoldipine is a 
potent coronary and peripheral vasodilator that 
maintains an increase in myocardial oxygen supply 
in excess of demand when given as an intravenous 
infusion. (Am J Cardiol 1988;58:1204-1208) 
0 f calcium channel blocking agents, dihydropyri- 
dine derivates form a distinct subgroup with an overall 
hemodynamic effect dominated by vasodilation. Ni- 
soldipine, an ester-substituted analog of nifedipine 
[Fig. l), exhibits greater smooth muscle selectivity than 
the parent compound, resulting in more potency as a 
vasodilator with fewer myocardial depressant effects1 
Electrophysiologic effects appear to be minimal at 
concentrations producing vascular changes2J Intrave- 
nous nisoldipine administered as a bolus has been 
studied in humans with suspected coronary artery dis- 
ease and was found to produce coronary and peripher- 
al vasodilation and to be free of major negative inotro- 
pit effects.4z5 An increase in coronary blood flow in 
excess of myocardial oxygen demand was consistently 
found, and such changes persisted for 20 minutes after 
acute administration.6 Clinical usefulness for paren- 
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teral nisoldipine remains to be confirmed, but extrapo- 
lation of these studies to disease states suggests that it 
may be of value in treatment of unstable angina or 
hypertensive crises. The present study investigates the 
coronary and systemic effects of nisoldipine given as 
an intravenous infusion over a 30-minute study period. 
Methods 
Thirteen patients (10 men, 3 women) with suspect- 
ed coronary artery disease or undergoing a follow-up 
study after coronary angioplasty were studied at the 
time of cardiac catheterization, All cardioactive medi- 
cations except for P-adrenergic blocking drugs when 
used and sublingual nitroglycerin as needed were dis- 
continued at least 24 hours previously. Any P-blocking 
drug was continued in the dosage prescribed by the 
referring physician. Mean age was 55 years (range 46 
to 63). The study protocol was performed before coro- 
nary angiography and left ventriculography with the 
patient fasting and without premeditation. No patient 
required sublingual nitroglycerin in the 12 hours pre- 
ceding study. A Webster 7Fr continuous thermodilu- 
tion catheter was inserted into the coronary sinus using 
a right antecubital approach in 12 patients and a right 
femoral venous route in 1 patient. A stable position 
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TABLE I Patient Clinical and Angiographic Data 
Dose Healed EF 
Pt Age (yr) & Sex fl Blocker (mg) Time (hr) AMI CAD (%) 
1 61M Metoprolol 2 x 200 4 + 3 0.43 
2 63F 0 0 0.72 
3 48M . 0 1 
4 54M 0 1 0.74 
5 57M Metoprolol 2 x 50 2 + 2 0.65 
6 6OF 0 0 0.76 
7 55M 0 0 0.55 
8 58M Atenolol 2 x 100 6 + 3 0.56 
9 58M Propranolol 3 x 40 4 + 1 0.61 
10 46M + 1 0.63 
11 51F Atenolol 1 x 100 5 0 0 0.78 
12 56M 0 1 0.55 
13 47M + 2 0.62 
Time (hr) = time in hours between last intake of P-blocking drug and study. 
AMI = acute myocardial infarction; CAD = coronary artery disease; EF = left ventricular ejection fraction, 
was achieved and verified by an initial 3-ml contrast 
injection and subsequent repeated fluoroscopy. Coro- 
nary venous blood flow was assessed by thermodilu- 
tion and the catheter allowed sampling of coronary 
venous blood for oxygen saturation analysis and cardi- 
ac pacing. A Swan-Ganz thermodilution catheter was 
positioned with the tip at the bifurcation of the main 
pulmonary artery for cardiac output determination 
and a 7Fr pigtail catheter was positioned in the ascend- 
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FIGURE 1. Chemical structures of the dihydropyridine derivatlves 
ing aorta for pressure measurements and arterial 
blood sampling. Baseline measurements were taken 
during both spontaneous heart rate and coronary ve- 
nous pacing at a rate approximately 20 beats/min 
above spontaneous rate. In sequence were measured, 
aortic and coronary venous oxygen saturations, coro- 
nary venous blood flow, aortic pressure and cardiac 
output. Heart rate was determined from continuous 
electrocardiographic monitoring. Nisoldipine, 4.5 
pg/kg, was given as a bolus over 3 minutes through the 
distal Swan-Ganz catheter lumen and followed imme- 
diately by an infusion of 0.2 pg/kg/min over a 3O- 
minute study period. Care was taken to minimize ni- 
soldipine exposure to light. At times 0, 8 and 16 
minutes after the bolus of nisoldipine, oxygen satura- 
tions and coronary blood flow were determined. At 24 
minutes after the bolus, oxygen saturations, coronary 
blood flow and cardiac output were determined dur- 
ing spontaneous heart rate and at a paced heart rate 
identical to that chosen for the control measurements. 
Aortic pressures were recorded at %minute intervals 
during the nisoldipine infusion, blood for nisoldipine 
levels taken before and 0,8,16 and 24 minutes after the 
bolus and hemoglobin concentration determined be- 
fore and after the study. Calculated parameters of aor- 
tic and coronary sinus oxygen contents were given by 
hemoglobin (g/100 ml) X oxygen saturation X 1.36, 
myocardial oxygen consumption by coronary venous 
blood flow X aortocoronary sinus oxygen difference 
and peripheral vascular resistance as the quotient of 
mean aortic pressure and cardiac output. Coronary 
vascular resistance was given as the quotient of mean 
aortic pressure and coronary blood flow. At the com- 
pletion of the study coronary and left ventricular angi- 
ographic examinations were performed using stan- 
dard techniques. Left ventricular ejection fractions 
were calculated from the right anterior oblique proj ec- 
tion using the area-length formula of Dodge. 
Statistical analysis: Values reported are mean f 
standard error of the mean, using &way analysis of 
variance [Duncan new multiple-range test) for repeat- 
ed measurements. When overall significance was 
found, multiple comparisons were used to delineate 
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which paired comparisons were significantly different 
at the 0.05 level. 
Results 
Five of the I3 patients were taking/3-blocking drugs 
at the time of study. Nine had significant coronary 
artery disease, defined as at least 50% luminal diame- 
ter narrowing in a major coronary artery, and mean 
ejection fraction was 0.63 (range 0.43 to 0.78). There 
was no significant difference in hemoglobin levels 
measured before and after the study. Patient clinical 
and angiographic data are summarized in Table I. One 
patient (no. I] had angina pectoris during control pac- 
ing but remained asymptomatic when matched pacing 
was performed during the nisoldipine infusion. No 
untoward symptom attributable to the nisoldipine was 
found in any patient. 
Heart rate increased from 71 f 4 to 82 f 5 (16 f 370, 
p K0.05) at the completion of the bolus and commence- 
ment of the 0.2~kg/kg/min infusion of nisoldipine 
(time = 0 minute]. The increase was 13 f 2% at 8 (p 
<O-05), 14 f 3% at 16 (p <O-05) and 15 f 3% at 24 
minutes (p <0.05) (Fig. 21. Initial systolic aortic pressure 
was I47 f 7 mm Hg and initial mean aortic pressure 
was 107 f 4 mm Hg. Nisoldipine produced significant 
(p <0.05) decreases in systolic aortic pressures of IS%, 
14%, 15% and 16% at times 0, 8,16 and 24 minutes, 
respectively. Decreases in mean aortic pressure at 0.8, 
16 and 24 minutes were 15 f 2%,11 f 2%,12 f 2% 
and 13 f 3%, respectively (all p <O.O5) (Fig. 2). Cardiac 
output increased from 5.7 f 0.4 liters/min to 7.4 f 0.5 
liters/min (33 f 6%, p <0.05) after 24 minutes, an 
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FIGURE 2. Heart rate (H.R.) and mean aortic pressure (AO) before 
and during nisoldipine infusion. Time 0 represents completion of the 
boius of 4.5pg/kg of nisoidiptne over 3 minutes and the immediate 
commencement of the 0.2-pg/kg/min infusion. 
increase due in part to the heart rate change but also to 
a I3 f 5% increase in stroke volume (p <O.O5). System- 
ic vascular resistance was simultaneously reduced by 
34 f 3% (p G.05). Coronary venous blood flow in- 
creased from 82 f 4 ml/min to 126 f 13 ml/min (f51 f 
9%, p <0.05) at 0 minute, to 118 f 13 ml/min (+42 f 
9%, p <0.053 at 8 minutes, to 108 f 8 ml/min (f31 f 
5%, p <O-05) at 16 minutes and to 111 f 10 (+34 & 6%, 
p X0.05) at 24 minutes after the commencement ofthe 
infusion. The decreases in coronary vascular resis- 
tance of 42 f 5%,35 f 6%,33 f 3% and 33 f 4% at the 
same intervals (all p <0.05) are illustrated, as are flow 
increases and myocardial oxygen consumption, in Fig- 
ure 3. Coronary venous oxygen saturations increased 
from 46 f 1% to 58 f 2% at 0 minute, 55 f 2% at 8,55 i 
2% at 16 minutes and 56 f 2% at 24 minutes (all p 
<O.O5). There was no change in the heart rate-systolic 
aortic pressure product. 
Hemodynamic results during matched coronary 
venous pacing are listed in Table II. 
Discussion 
The peripheral vasodilatory action of the dihydro- 
pyridines in reducing left ventricular afterload, when 
combined with reflex adrenergic stimulation’,* serve 
to increase cardiac output and mask the intrinsic nega- 
tive inotropic effects of these compounds apparent in 
in vitro experiments9 and during intracoronary admin- 
istration.1° Reflex adrenergic stimulation may produce 
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FIGURE 3. Coronary venous blood flow (C.V.B.F.) and calculated 
coronary vascular reststance (C.V.R.) vs time after commence- 
ment of nisoidiplne infusion, The lower p/of is of myocardial oxygen 
consumption (MV0.s). None of the changes in myocardiai oxygen 
consumption were statistically significant. 
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TABLE II Hemodynamic Effects During Matched Pacing 
Control Nisoldipine % Change p Value 
HR (beats/min) 
Systolic Ao (mm Hg) 
Mean Ao (mm Hg) 
CO (liters/min) 
SV (ml) 
SVR (dynes s cmm5) 
CVBF (ml/min) 
CVR (mm Hg/ml/min) 
MVO, (ml/min/lO-‘) 
91 
149 f 7 
113 f 5 
6.5 f 0.4 
73 f 5 
19 f 2 
104 i 7 
1.15 It 0.07 
93 f 6 
91 
123 f 3 
94 f 2 
8.2 f 0.6 
91 f 7 
12 f 1 
125 f 13 
0.85 f 0.08 
89 f 8 
-17 0.001 
-17 0.001 
+26 0.0001 
+24 0.005 
-34 0.0001 
+20 0.05 
-26 0.0001 
-4 NS 
Changes induced by nisoldipine infusion on various parameters during matched coronary sinus pacing. 
AO = aortic pressure: CO = cardiac output; CVBF = coronary venous blood flow; CVR = coronary vascular 
resistance; HR = heart rate; MVO, = myocardial oxygen consumption; NS = not significant; SV = stroke volume; 
SVR = systemic vascular resistance. 
an oxygen-wasting effect by increasing inotropic state, 
as suggested by the increases in calculated myocardial 
consumption at 0 and 8 minutes after the nisoldipine 
bolus (p = 0.07 and p = 0.06, respectively). The heart 
rate-systolic aortic pressure product showed opposite 
trends (difference not significant [NS]), but this esti- 
mation of myocardial oxygen demand is insensitive to 
changes in inotropic state. Oxygen consumption had 
returned to control values during infusion at 16 and 24 
minutes after the bolus, and was unchanged when 
heart rate was fixed by matched pacing. Thus, the 
increase in coronary blood flow during spontaneous 
heart rate and matched pacing indicates increased 
myocardial oxygen supply in excess of demand, and 
these changes may be maintained in a steady state 
during short-term infusion of nisoldipine. 
The nisoldipine infusion produced a stable in- 
crease in heart rate and decrease in aortic pressure. 
The increase in heart rate offsets any reduction in 
cardiac work secondary to reduced afterload, and this 
seems a reasonable rationale for combination use with 
a P-blocking drug for treatment of hypertension or 
myocardial ischemia. The 5 patients in the study group 
taking ,&blocking drugs had smaller increases in heart 
rate (11% vs 17%, NS), a slightly greater decrease in 
mean aortic pressure (14% vs ll%, NS) and a different 
trend in myocardial oxygen consumption (-5% vs 
+lO%, NS). In anesthetized pigs, the responses to ni- 
soldipine in arterial blood pressure, cardiac output 
and systemic vascular resistance were unchanged by /3 
blockade, but the elevations in heart rate and maximal 
left ventricular dP/dt were abolished,ll as was the 
decrease in left ventricular filling pressure, an effect 
of nisoldipine shown in other studies.12 The decreases 
in systemic and coronaiy vascular resistances of 36% 
and 3l%, respectively, during spontaneous heart rate 
and decreases of 34% and 26% during matched pacing 
were of similar magnitude and did not support the 
proposal that nisoldipine exhibits greater coronary 
vascular than peripheral sensitivity. Nisoldipine has a 
preferential action and greater potency on vascular 
smooth muscle than nifedipine, so that vasodilatory 
changes can be obtained with less tendency to depress 
myocardial function. These vasodilatory effects with 
an absence of negative inotropic effects have formed 
the basis for studies investigating oral nisoldipine in 
patients with chronic heart failure.13-I5 
Oral nisoldipine has been shown in recent clihical 
trials to have antianginal propertieC-l8 in patients 
with stable, exercise-induced angina and in patients 
with variant angina, lg but the value of intravenous 
nisoldipine in the blinical situation awaits further 
evaluation. Our study has shown nisoldipine to be a 
potent coronaiy and peripheral vasodilator, to in- 
crease myocardial oxygen supply in excess of demand 
and in infusion administration, and to maintain these 
changes in a stable state over a 30-minute study period. 
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